Skip to main content
SpringerLink
Log in

Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Glioblastoma is the commonest neuroectodermal tumor and the most malignant in the range of cerebral astrocytic gliomas. The prognostic utility of various biological markers for glioblastomas has been broadly tested but the results obtained are regarded as controversial. In the present study, 302 glioblastoma specimens were studied to evaluate a possible association between clinical outcome and expression of some immunohistochemical variables. Furthermore, tumors examined were subdivided on the three cytological subsets – small-cell (SGB), pleomorphic-cell (PGB) and gemistocytic (GGB). Immunohistochemical variables differed between various subsets: the number of p53-positive tumors was found to be prevailed among the PGB, whereas the number of tumors with EGFR and mdm2 positivity was significantly greater in SGB. GGB contained significantly lowest mean proliferating cell nuclear antigen (PCNA) labeling index (LI), greater number of p21ras positive cases, and higher mean apoptotic index (AI). Survival time in patients with SGB, EGFR and mdm2-positivity and PCNA LI >40% was found to be significantly shorter, whereas presence of p21ras and AI >0.5% were associated with prolonged survival. Multivariate analysis revealed that survival time is associated with SGB, EGFR-positivity, and AI (p = 0.0023, p = 0.0035 and p = 0.0029 respectively). We conclude that although some immunohistochemical variables were found to be significant for glioblastoma outcome, they appear to be closely related to biology of single cytological subsets. Furthermore, these variables exhibited no prognostic value when they were analyzed within each cytological subset separately. Therefore, the glioblastoma subdivision on three cytological subsets proposed by us is carrying some element of rationality but, undoubtedly, requires further prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM: Tumors of central neuroepithelial origin. In: Bigner DD, McLendon RE, Bruner JM (eds) Russel and Rubinstein's Pathology of Tumors of the Nervous System. vol. 1, 6th edn. Arnold, London, 1998, pp. 387-417

    Google Scholar 

  2. Kleihues P, Cavenee WK: Tumors of the Nervous System. Pathology and Genetics: World Health Organization International Classification ofTumours. IARC press, Lyon, 2000, pp. 72-81

    Google Scholar 

  3. Barker FG II, Chang SM, Larson DA, Sneed P, Wara WM, Wilson CB, Prados MD: Age and radiation respose in glioblastoma multiforme. Neurosurgery 49: 1288-1298, 2001

    Google Scholar 

  4. Barker FG II, Davis RL, Chang SM, Prados MD: Necrosis as prognostic factor in glioblastoma multiforme. Cancer 77: 1161-1166, 1996

    Google Scholar 

  5. Chandler KL, Prados MD, Malec M, Wilson CB: Longterm survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993

    Google Scholar 

  6. Cohadon F, Aouad N, Rougier A, Vital C, Rivel J, Dartigues JF: Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neuro-Oncol 3: 105-111, 1985

    Google Scholar 

  7. Hess KR: Extent of resection as a prognostic variable in the treatment gliomas. J Neuro-Oncol 42: 227-231, 1999

    Google Scholar 

  8. Kreth FW, Berlis A, Spiropouolou V, Faist M, Scheremet R, Rssoner R, Volk B, Ostertag CB: The role of tumor resection in the treatment of glioblastoma multiforme. Cancer 86: 2117-2123, 1999

    Google Scholar 

  9. Lacroix M, AbiSaid D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001

    Google Scholar 

  10. Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR: Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro-Oncol 27: 259-266, 1996

    Google Scholar 

  11. Salcman M, Scholtz H, Kaplan RS, Kulik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994

    Google Scholar 

  12. Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P: Long-term glioblastoma multiforme survivors: a population based study. Can J Neurol Sci 25: 197-201, 1998

    Google Scholar 

  13. Schrieve DC, Alexander E, Black PMcL, Wen PY, Fine HA, Kooy HM, Loeffler JS: Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72-77, 1999

    Google Scholar 

  14. Vertosick FT, Selker RG: Long-term survival after the diagnosis of malignant glioma. A series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 38: 359-363, 1992

    Google Scholar 

  15. Al-Sarraj S, Bridges LR: p53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 9: 143-149, 1995

    Google Scholar 

  16. Ang LC, Plewes M, Tan L, Begley H, Agranovich A, Shul D: Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 21: 306-310, 1994

    Google Scholar 

  17. Barker FG II, Prados MD, Chang SM, Davis RL, Gutin PH, Lamborn KR, Larson DA, McDermott MW, Snned PK, Wilson CB: Bromdeoxiuridine labeling index in glioblastoma multiforme: Relation to radiation responce, age, and survival. Int J Radiat Oncol Biol Phys 34: 803-808, 1996

    Google Scholar 

  18. Barker FG II, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, Alpade KD: EGFR expression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 410-418, 2001

    Google Scholar 

  19. Baxendine-Jones J, Campblell I, Ellison D: P53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 16: 332-336, 1997

    Google Scholar 

  20. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Doufor H, Figarella-Branger D: Prognostic significance of Ki-67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 24: 318-388, 1998

    Google Scholar 

  21. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Alpade KD: Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res 8: 180-187, 2002

    Google Scholar 

  22. Chakravarti A, Delaney MA, Noll E, Black PMcL, Loeffler JS, Muzikansky A, Dyson NJ: Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7: 2387-2395, 2001

    Google Scholar 

  23. Chozick BS, Pezullo JC, Epstein MH, Finch PW: Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 35: 831-838, 1994

    Google Scholar 

  24. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg 86: 121-130, 1997

    Google Scholar 

  25. Deininger MH, Grote E, Wickboldt J, Meyermann R: Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and bcl-2 in glioblastoma multiforme relapses in vivo. J Neuro-Oncol 48: 121-129, 2000

    Google Scholar 

  26. Diedrich U, Lucius J, Baron E, Behnke J, Pabst B, Zoll V: Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis. J Neurol 242: 638-688, 1995

    Google Scholar 

  27. Dorward NL, Hawkins RA, Whittle IR: Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma. Br J Neurosurg 7: 197-199, 1993

    Google Scholar 

  28. Ehrmann JJ, Kolar Z, Vojtesek B, Kala M, Komenda S, Oulto A: Prognostic factors in astrocytomas: relationship of p53, MDM2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival. Neoplasma 44: 299-304, 1997

    Google Scholar 

  29. Ellison DW, Steart PV, Bateman AC, Pickering RM, Palmer JD, Weller RO: Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatr 59: 413-419, 1995

    Google Scholar 

  30. Etienne M-C, Formento J-L, Lebrun-Frenay C, Gioanni G, Chatal M, Paquis P, Bernard C, Courdi A, Bensadoun R-J, Pignol J-P, Francoual M, Grellier P, Frenay M, Milano G: Epidermal growth factor receptor and labelling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 4: 2383-2390, 1998

    Google Scholar 

  31. Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD: Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 13: 717-724, 1998

    Google Scholar 

  32. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, Kimmel DW: Prognostic factors in gliomas. A multivariate analysis of clinical pathological, flow cytometric, cytogenetic, and molecular markers. Cancer 74: 920-927, 1994

    Google Scholar 

  33. Grunnet ML, O'Neil A, Gilbert M: Correlation of tumor p53 and PCNA with response and survival of glioblastoma in pateints treated with an ECOG protocol of preirradiation chemotherapy. Clin Neuropathol 19: 230-234, 2000

    Google Scholar 

  34. Hara A, Saegusa M, Mikami T, Okayasu I: Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J Clin Pathol 54: 860-865, 2001

    Google Scholar 

  35. Heesters MAAM, Koudstaal J, Go KG, Molenaar WM: Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neuro-Oncol 44: 255-266, 1999

    Google Scholar 

  36. Heisiger EM, Hayes RL, Pierz DM, Budzilovich GN: Prognostic relevance of epidermal growth factor receptor (ERF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neuro-Oncol 16: 93-104, 1993

    Google Scholar 

  37. Holden JA, Townsend JJ: DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 12: 1094-100, 1999

    Google Scholar 

  38. Huhn SL, Mohapatra G, Bollen A, Lamborn K, Prados MD, Feuerstein BG: Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization: correlation with radiaton treatment. Clin Cancer Res 5: 1435-1443, 1999

    Google Scholar 

  39. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J: Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51: 84-90, 1992

    Google Scholar 

  40. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag AM: Prognostic implication of p53 protein, epidermal growth factor receptor and Ki-67 labelling in brain tumor. Br J Cancer 66: 373-385, 1992

    Google Scholar 

  41. Karkavelas G, Mavropoulu S, Fountzilas G, Christoforidou V, Karavelis A, Foroglou G, Papadimitrou C: Correlation of proliferating cell nuclear antigen assessment histologic parameters and age with survival in patients with glioblastoma multiforme. Anticancer Res 15: 531-536, 1995

    Google Scholar 

  42. Kleinschmidt-DeMasters BK, Evans LC, Bobal JB, Lopez-Uribe D, Hopper D, Shroyer AL, Shroyer KR: Quantitative telomerase expression in glioblastomas shows regional variations and down-regulation with therapy but not correlation with patients outcome. Hum Pathol 31: 116-127, 2000

    Google Scholar 

  43. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, Seretis A, Thomas-Tsagli E: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferating markers and epidermal growth factors receptor. Br J Cancer 75: 1269-1278, 1997

    Google Scholar 

  44. Korkolopoulou PA, Konstantinidou AE, Patsorius ES, Christodoulou PN, Thomas-Tsagli EA, Davaris PS: Detection of apoptotic cells in archival tissue from diffuse astrocytomas using a monoclonal antibody to single-stranded DNA. J Pathol 193: 377-382, 2001

    Google Scholar 

  45. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U: Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neuro-Oncol 48: 89-94, 2000

    Google Scholar 

  46. Kraus JA, Wenghoefer M, Glesmann N, Mohr C, Beck M, Schmidt MC, Schroder R, Berwieler U, Roggendorf W, Diete S, Deitzmann K, Heuser K, Muller B, Fimmers R, von Deimling A, Schlegel U: TP53 gene mutations, nuclear p53 accumulation, expression Waf/p21, bcl-2 and CD95(APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neuro-Oncol 52: 263-272, 2001

    Google Scholar 

  47. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM: Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinogen 15: 14-18, 1996

    Google Scholar 

  48. Leenstra S, Oskam NT, Bijleveld EH, Bosch DA, Troost D, Hulsebos TJ: Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer 79: 159-165, 1998

    Google Scholar 

  49. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA: Malignant glioma: genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001

    Google Scholar 

  50. Montine TJ, Bruner JM, Vandersteenhoven JJ, Dodge RK, Burger PC: Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms. Diagn Mol Pathol 3: 240-254, 1994

    Google Scholar 

  51. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns B, Bruner JM: Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 34: 674-679, 1994

    Google Scholar 

  52. Newcomb EW, Cohen H, Le SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2, or bcl-2 genes. Brain Pathol 8: 655-667, 1998

    Google Scholar 

  53. Nieder C, Petersen S, Petersen C, Thames HD: The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev 26: 67-73, 2000

    Google Scholar 

  54. Nishizaki T, Kubota H, Harada K, Harada K, Ito H, Suzuki M, Sasaki K: Clinical evidence of distinct subgoups of astrocytic tumors defined by comparative genomic hybridization. Hum Pathol 31: 608-614, 2000

    Google Scholar 

  55. Olson JJ, Barnett D, Yang J, Assietti R, Cotsonins G, James CD: Gene amplification as a prognostic factor in primary brain tumors. Clin Cancer Res 4: 215-222, 1998

    Google Scholar 

  56. Pigott TJD, Lowe JS, Palmer J: Statistical modeling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg 5: 61-66, 1991

    Google Scholar 

  57. Pigott TJD, Robson DK, Palmer J, Ward LM: Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg 7: 261-265, 1993

    Google Scholar 

  58. Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschläger C, Heidecke V, Burkert W: Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neuro-Oncol 35: 13-28, 1997

    Google Scholar 

  59. Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Packer RJ, Mehta R, Fruehauf JP, Brem H: The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neuro-Oncol 55: 195-201, 2001

    Google Scholar 

  60. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R: BCL-2 family protein expression in human malignant glioma. A clinical-pathological correlative study. J Neurol Sci 155: 68-75, 1998

    Google Scholar 

  61. Rhodes RH: Biological evaluation of biopsies from adult cerebral astrocytomas: cell-growth/cell-suicide ratios and their relationship to patient survival. J Neuropathol Exp Neurol 57: 746-757, 1998

    Google Scholar 

  62. Rodriguez-Pereira C, Suarez-Peneranda JM, Barros F, Sobrido MJ, Vazquez-Salvado M, Fortez J: Analysis of 2 antiapoptotic factors in gliomas. bcl-2 overexpression and p53 mutation. Arch Pathol Lab Med 125: 218-223, 2001

    Google Scholar 

  63. Sallinen PK, Haapasalo HK, Visakorpi T, Helin PT, Rantala IS: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275-282, 1994

    Google Scholar 

  64. Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, Hess KR, Myers JN, Hong YK, Yung WKA, Steck PA: Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820-1824, 1999

    Google Scholar 

  65. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes M, Kiessling M: Amplification of epidermalgrowth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 56: 72-77, 1994

    Google Scholar 

  66. Schober R, Bilzer T, Waha A, Reifenberger J, Wechsler W, von Demling A, Wiestler OD, Westphal M, Kemshead JT, Vega F, Delattre JY, Stasiecki-Steinfeld P: The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression and patient survival data in a therapeutic trial. Clin Neuropathol 14: 169-174, 1995

    Google Scholar 

  67. Simmons ML, Lamborn KL, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG II, Alpade K: Analysis of complex relationships between age, p53, EGFR, and survival in glioblastoma patients. Cancer Res 61: 1122-1128, 2001

    Google Scholar 

  68. Smith JS, Jenkins RB: Genetic alteration in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci 5: D213-D231, 2000

    Google Scholar 

  69. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB: PTEN mutation, EGFR amplification and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246-1256, 2001

    Google Scholar 

  70. SoiniY, Nyemela A, Kamel D, Herva R, Bloigu R, Pekki P: p53 immunohistichemcial positivity as a prognostic marker in intracranial tumours. APMIS 102: 786-792, 1993

    Google Scholar 

  71. Stemmer Rachamimov AO, Louis DN: Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 9: 230-234, 1997

    Google Scholar 

  72. Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T: High cyclin E/lowp27kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol (Berl) 101: 334-340, 2001

    Google Scholar 

  73. Taniguchi K, Wakabayashi T, Yoshida T: Immunohistochemical staining of DNA topoisomerase II a in human gliomas. J Neurosurg 91: 477-482, 1999

    Google Scholar 

  74. Theunissen PHMH, Blaauw J: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytomas. Histopathology 23: 75-79, 1993

    Google Scholar 

  75. Torp SH, Helseth E, Dalen A, Unsgaard G: Relationship between Ki-67 labelling index, amplification of epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien) 117: 182-186, 1992

    Google Scholar 

  76. Vaquero J, Zurita M, Morales C, Oya S, Coca S: Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma. J Neuro-Oncol 46: 11-16, 2000

    Google Scholar 

  77. Waha A, Baumann A, Wolf HK, Fimmers R, Neumann J, Kindermann D, Astrahantseff K, Blumke A, von Deimling A, Schlegel U: Lack of prognostic relevance of alterations in epidermal growth factor receptortransforming growth factor a pathway in human astrocytic gliomas. J Neurosurg 85: 634-641, 1996

    Google Scholar 

  78. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive radiation. Int J Radiat Oncol Biol Phys 34: 809-815, 1996

    Google Scholar 

  79. Golanov A, Korshunov A: Immunohistochemical study of proliferative activity and p53 oncoprotein expression in different cytological phenotypes of the cerebral glioblastomas. Clin Neurol Neurosurg 99(Suppl 1): 30, 1997

    Google Scholar 

  80. Burger PC, Vollmer RT: Histologic factors of prognostic significance in the glioblastoma multiforme. Cancer 46: 1179-1186, 1980

    Google Scholar 

  81. Burger PC, Vogel S, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985

    Google Scholar 

  82. Burger PC, Green SB: Patient age, histological features and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625, 1997

    Google Scholar 

  83. Giangaspero F, Burger PC: Correlations between cytologic composition and biologic behavior in the glioblastoma multiforme. A postmortem study of 50 cases. Cancer 52: 2320-2333, 1983

    Google Scholar 

  84. Kraus JA, Wenghoefer M, Schmidt MC, von Deimling A, Berwieler U, Roggendorf W, Diete S, Deitzmann K, Heuser K, Muller B, Heuser K, Reifenberger G, Schlegel U: Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. J Neurol 247: 455-460, 2000

    Google Scholar 

  85. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hsu L: p53-dependent G 1 arrest and p53 independent apoptosis influence the radiobiologic response of gliobalstoma. Int J Radiat Oncol Biol Phys 36: 95-103, 1996

    Google Scholar 

  86. Kraus A, Gross MW, Knuechel R, Munkel K, Neff F, Schlegel J: Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53. J Neurosurg 93: 863-872, 2000

    Google Scholar 

  87. Tribius S, Pidel A, Casper D: ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. J Radiat Oncol Biol Phys 50: 511-523, 2001

    Google Scholar 

  88. Shu HKG, Kim MM, Chen P: The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21-BAX expression. Proc Natl Acad Sci 95: 399-403, 1998

    Google Scholar 

  89. Haas-Kogan DA, Kogan SS, Yount J, Hsu H, Haas M, Deen DF, Israel MA: p53-function influences the effect of fractionated radiotherapy on gliobalstoma tumors. Int J Radiat Oncol Biol Phys 43: 399-403, 1999

    Google Scholar 

  90. Tada M, Matsumoto R, Igga RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y: Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutation. Cancer Res 40: 57-63, 1998

    Google Scholar 

  91. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J Neuropathol Exp Neurol 56: 180-185, 1997

    Google Scholar 

  92. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H: Short alternative splice transcripts of the mdm2 oncogene correlate to maligancy in human astrocytic neoplasms. Cancer Res 58: 609-613, 1998

    Google Scholar 

  93. Ellison DW, Steart PV, Gatter KC, Weller RO: Apoptosis in cerebral astrocytic tumors and its relationship to expression of BCL-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361, 1995

    Google Scholar 

  94. Krajewski S, Krajewska M, Ehramann J, Sikorska M, Lach B, Chatten J: Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1 and Bax in tumors of central and peripheral nervous system. Am J Pathol 150: 805-814, 1997

    Google Scholar 

  95. Krishna M, Smith TW, Recht LD: Expression of bcl-2 in reactive and neoplastic astrocytes: lack of correlation with presence of degree of malignancy. J Neurosurg 83: 1017-1022, 1995

    Google Scholar 

  96. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J: Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol (Berl) 88: 520-526, 1994

    Google Scholar 

  97. Schiffer D, Cavalla P, Migheli A, Giordana MT, Chiado-Piat L: Bcl-2 distribution in neuroepithelial tumors: an immunohistochemical study. J Neuro-Oncol 27: 101-109, 1996

    Google Scholar 

  98. Weiner H: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 37: 179-194, 1995

    Google Scholar 

  99. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, Collins VP: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastoma with EGFR gene amplification. Oncogene 9: 2313-2320, 1994

    Google Scholar 

  100. Luwor RB, Johns TG, Murone C, Huang H-JS, Cawenee WK, Ritter G, Old LJ, Burgess A, Scott AM: Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61: 5355-5361, 2001

    Google Scholar 

  101. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ: Monoclonal antibodies against EGFr vIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148, 1995

    Google Scholar 

  102. Nagane M, Coufal F, Lin H, Bhogler O, Cavenee WK, Huang HJ: A common mutant epidermal growth factor receptor enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086, 1996

    Google Scholar 

  103. Nagane M, Lin H, Cavenee WK, Huang HJ: Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 162: 17-21, 2001

    Google Scholar 

  104. Feun LJ, Savaraj N, Landy HJ: Drug resistance in brain tumors. J Neuro-Oncol 20: 165-176, 1994

    Google Scholar 

  105. Beiswanger CM, Diegmann MH, Novak RF, Philbert MA, Garessle TL, Reuhl KR, Lowndes HE: Developmental changes in the cellular distribution of glutathione and glutathione S-transferases in murine nervous system. Neurotoxicology 16: 425-440, 1995

    Google Scholar 

  106. Philbert MA, Bieswanger CM, Manson MM, Green 2JA, Novak RF, Primiano T, Reuhl KR, Lowndes HE: Glutathione S-transferases and gamma-glutamyl transpeptidase in the rat nervous systen: a basis for differential susceptibility to neurotoxicants. Neurotoxicology 16: 339-342, 1995

    Google Scholar 

  107. Ali-Osman F, Brunner JM, Kultuk TM, Hess K: Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 3: 2253-2261, 1997

    Google Scholar 

  108. Bossanyi von P, Diete S, Dietzmann K, Warich Kirches M, Kirches E: Immuno-histochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol (Berl) 94: 605-611, 1997

    Google Scholar 

  109. Strange RC, Lear JT, Fryer AA: Polymorphism in glutathione S-transpherase loci as a risk factor for common cancers. Arch Toxicol Suppl 20: 419-428, 1998

    Google Scholar 

  110. Besson A, Yong VW: Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas. J Neuro-Oncol 51: 245-264, 2001

    Google Scholar 

  111. Fults D, Petronio J, Noblett BD, Pedone CA: Chromosome 11p15 deletions in human malignant astrocytomas and primitive neuroectodermal tumors. Genomics 14: 799-801, 1992

    Google Scholar 

  112. Blumenstock M, Prosenc N, Patt S, Pfanne K, Drum F, Cervos-Navarro J: In contrast to EGFr gene overexpression, H-ras gene expression decreases in human gliomas. Anticancer Res 11: 1353-1357, 1991

    Google Scholar 

  113. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A: Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma specimens. Neurosurgery 45: 1442-1453, 1999

    Google Scholar 

  114. Gomori E, Doszi T, Pajor L, Matolcsy A: Sporadic p53 mutations and absence of ras mutations in glioblastomas. Acta Neurochir (Wien) 141: 593-599, 1999

    Google Scholar 

  115. Sonoda Y, Ozawa T, Alpade KD, Deen DF, Berger MS, Pieper RO: Akt pathways activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61: 6674-6678, 2001

    Google Scholar 

  116. Sonoda Y, Ozawa T, Hirose Y, Alpade KD, McMahon M, Berger MS, Pieper RO: Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960, 2001

    Google Scholar 

  117. Salgaller M, Pearl D, Stephens R: In situ hybridization with single stranded RNA probes to demonstrate infrequently elevated gli mRNA and no increased ras mRNA levels in meningiomas and astrocytomas. Cancer Lett 57: 243-253, 1991

    Google Scholar 

  118. Bian XW, Shi JQ, Liu FX: Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors. Anal Quant Cytol Histol 22: 429-437, 2000

    Google Scholar 

  119. Gulbins E, Bissonnete R, Mahboubi A: Fas-induced apoptosis is mediated via a ceramide initiated RAS signaling pathway. Immunity 2: 341-351, 1995

    Google Scholar 

  120. Croce CM: How can we prevent cancer ? Proc Natl Acad Sci USA 98: 10986-10988, 2001

    Google Scholar 

  121. Langlois NE, Eremin O, Heys SD: Apoptosis and prognosis in cancer: rationale and relevance. J R Coll Surg Edinb 45: 211-219, 2000

    Google Scholar 

  122. Tamm I, Schriever F, Droken B: Apoptosis: implication of basic research in clinical oncology. Lancet Oncol 2: 33-42, 2001

    Google Scholar 

  123. Savitz SI, Rosenbaum DM: Apoptosis in neurological desease. Neurosurgery 42: 555-574, 1998

    Google Scholar 

  124. Carrol RS, Zhang J, Chauncey BW: Apoptosis in atrocytic neoplasms. Acta Neurochir (Wien) 139: 845-850, 1997

    Google Scholar 

  125. Kordek R, Hironoshi N, Liberski PP, Yanagihara R, Gajdushek DC: Apoptosis in glial tumors as determined by in situ nonradioactive labeling of DNA breaks. Acta Neuropathol (Berl) 91: 112-116, 1996

    Google Scholar 

  126. Kokunai T, Sawa H, Tamaki N: Localization of apoptotic cells in situ of brain tumors. Brain Tumor Pathol 12: 15-21, 1995

    Google Scholar 

  127. Migheli A, Cavalla P, Marino S, Schiffer D: A study of apoptosis in normal and pathological nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 53: 606-616, 1994

    Google Scholar 

  128. Mizoguchi M, Inamura T, Shono T, Ikezaki K, Inoha S, Ohgama S, Fukui M: A comparative study of apoptosis and proliferation in germinoma and glioblastoma. Neuro-Oncology 2: 96-102, 2000

    Google Scholar 

  129. Patsouris E, Davaki P, Kapranos N, Davaris P, Papageorgiou K: A study of apoptosis in brain tumors by in situ end-labelling method. Clin Neuropathol 15: 337-341, 1996

    Google Scholar 

  130. Yew DT, Wang HH, Zheng DR: Apoptosis in astrocytomas with different grades of malignancy. Acta Neurochir (Wien) 140: 341-347, 1998

    Google Scholar 

  131. Imitola J, Nikas DS, Black PMcL: Apoptosis in tumors of the central nervous system. Crit Rev Neurosurg 7: 391-399, 1997

    Google Scholar 

  132. Nakatsu S, Kondo S, Yin D, Peterson JV, Kaakaji R, Morimura T: Induction of apoptosis in multi-drug resistance (MDR) human glioblastoma cells by SN-38, a metabolite of the campothecin deprivate CTP 11. Cancer Chemother Pharmacol 71: 417-423, 1997

    Google Scholar 

  133. Scherer HJ: The forms of growth in gliomas and their practical significance. Brain 63: 1-35, 1940

    Google Scholar 

  134. Kleihues P, Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1: 44-51, 1999

    Google Scholar 

  135. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 3: 19-26, 1993

    Google Scholar 

  136. Burger PC, Pearl DK, Aldape K, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB, James CD: Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60: 1099-1104, 2001

    Google Scholar 

  137. Tachibana O, Lampe J, Kleihues P, Ohgaki H: Preferntial expression of Fas/APO (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431-434, 1996

    Google Scholar 

  138. Tohma Y, Gratas C, Van Meir EG, Disbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H: Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57: 239-245, 1998

    Google Scholar 

  139. Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 159: 779-786, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropathology, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Korshunov & Regina Sycheva

  2. Department of Neuro-oncological Surgery, Neurosurgical NN Burdenko Institute, Moscow, Russia

    Andrey Golanov

Authors
  1. Andrey Korshunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrey Golanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Regina Sycheva
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korshunov, A., Golanov, A. & Sycheva, R. Immunohistochemical Markers for Prognosis of Cerebral Glioblastomas. J Neurooncol 58, 217–236 (2002). https://doi.org/10.1023/A:1016218117251

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016218117251

Search

Navigation